Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.
Type:
Application
Filed:
January 27, 2017
Publication date:
January 31, 2019
Applicants:
INSERM (Institut National De La Santé et de La Recherche Médicale, Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse
Inventors:
Thierry LEVADE, Nicolas MEYER, Céline COLACIOS VIATGÉ, Caroline IMBERT, Nathalie ANDRIEU-ABADIE, Bruno SEGUI
Abstract: Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors. The invention concerns a kit-of-parts comprising 5?-hydroxy-6?-[2-(1H-imidazol-4-yl)ethylamino]cholestan-3?-ol (Dendrogenin A) or a pharmaceutically acceptable salt thereof and an antineoplastic agent for use in the treatment of cancer. Furthermore, the invention concerns Dendrogenin A or a pharmaceutically acceptable salt thereof for use for treating a chemoresistant cancer.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
January 29, 2019
Assignees:
AFFICHEM, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Inventors:
Philippe de Medina, Michael Paillasse, Christian Recher, Marc Poirot, Sandrine Silvente Poirot
Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
Type:
Grant
Filed:
May 12, 2015
Date of Patent:
December 4, 2018
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud, Universite Paul Sabatier Toulouse III
Inventors:
Bruno Segui, Nathalie Andrieu-Abadie, Thierry Levade, Celine Colacios Viatge, Philippe Rochaix, Florie Bertrand, Herve Benoist, Julia Rochotte
Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
Type:
Grant
Filed:
April 23, 2015
Date of Patent:
April 17, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Abstract: The invention relates to a device for capture of cellular biomarkers circulating in an animal or human biological flow, characterised in that it is suitable for use in vivo and in that it comprises a means of filtration intended to retain the said cellular biomarkers, the said means of filtration comprising at least one through-aperture the dimensions of which are suitable for retaining the said cellular biomarkers and being integral with a support, the support taking the form of a hollow component.
Type:
Application
Filed:
February 2, 2016
Publication date:
February 22, 2018
Applicants:
Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Universite Toulouse III - Paul Sabatier
Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.
Type:
Grant
Filed:
January 7, 2015
Date of Patent:
December 26, 2017
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse, Universite de Bourgogne, Universite de Rennes I, Universit des Antilles et de la Guiyane, Ecole des Hautes Etudes en Sante Publique (EHESP)
Inventors:
Patrick Legembre, Bruno Segui, Thierry Levade, Olivier Micheau
Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.
Type:
Application
Filed:
October 29, 2015
Publication date:
August 31, 2017
Applicants:
Syntivia, Centre Hospitalier Universitaire de Toulouse, Universite Paul Sabatier - Toulouse III, Centre National de la Recherche Scientifique
Inventors:
Marine Norlund, Bernard Ducommun, Philippe Bedos, Valérie Lobjois
Abstract: A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.
Type:
Grant
Filed:
April 24, 2013
Date of Patent:
May 2, 2017
Assignees:
UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, INVIVOGEN
Inventors:
Antoine Blancher, Nicolas Congy, Jean-Gerard Tiraby, Daniel Drocourt
Abstract: The invention relates to a ternary lipid association of ?-sitosterol, isocetyl stearoyl stearate and glyceryl tri-2-ethylhexanoate, wherein the ?-sitosterol content of said association is between 0.1% and 5 wt. %.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
April 11, 2017
Assignees:
PIERRE FABRE DERMO-COSMETIQUE, UNIVERSITE PARIS-SUD 11, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Inventors:
Hélène Duplan, Daniel Redoules, Alexandre Delalleau
Abstract: The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient.
Type:
Grant
Filed:
May 31, 2012
Date of Patent:
August 9, 2016
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER—TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE de TOULOUSE
Abstract: The invention relates to a ternary lipid association of ?-sitosterol, isocetyl stearoyl stearate and glyceryl tri-2-ethylhexanoate, wherein the ?-sitosterol content of said association is between 0.1% and 5 wt. %.
Type:
Application
Filed:
July 11, 2014
Publication date:
June 16, 2016
Applicants:
PIERRE FABRE DERMO-COSMETIQUE, UNIVERSITE PARIS-SUD 11, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Inventors:
Hélène DUPLAN, Daniel REDDULES, Alexandre DELALLEAU
Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
Type:
Application
Filed:
April 23, 2015
Publication date:
August 13, 2015
Applicants:
Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
Type:
Grant
Filed:
January 25, 2012
Date of Patent:
June 9, 2015
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
Type:
Application
Filed:
January 25, 2012
Publication date:
November 21, 2013
Applicants:
Institut National de la Sante et de la Recherche Medicale(Inserm), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE